| 查看: 587 | 回复: 1 | ||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | ||
yaping221木虫 (正式写手)
|
[求助]
脂组学类翻译，谢谢！
|
|
|
In future personalized medicine enabled by lipidomics and metabolomic may expedite the mission of the right patients receiving the right drug at the right time and dose. Recently more potent drugs including monoclonal antibodies able to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) and inflammatory pathways have been developed to improve current CAD care. However, these novel targeted treatments seem to be at present too expensive to be widely used among all CAD patients. Thus, sensitive biomarkers are needed for identification of patients most suitable for novel innovative treatments and the metabolomic and lipidomic biomarker candidates, in particular the ceramides, hold the potential to become clinically useful companion diagnostics of the future. |
回复此楼» 猜你喜欢
生命口C13面上会评时间
已经有11人回复
-
内心匮乏
已经有16人回复
-
生命口面上会评结束了吗大家有知道结果吗？现在还没有结果正常不？
已经有9人回复
-
有机物中金属离子降到1ppm以下，有什么好的方法吗？用过有机溶剂重结晶还是降不下来
已经有4人回复
-
投英文期刊如何查重
已经有6人回复
-
不要再数国自然申请书的 filecode 的分隔符个数了
已经有21人回复
-
伯胺上甲基求助
已经有7人回复
-
跨出版社商投稿
已经有5人回复
-
5个%2F，非固定段22个字母
已经有7人回复
-
生生命学部会评
已经有4人回复
genhunter
至尊木虫 (著名写手)
- 翻译EPI: 387
- 应助: 259 (大学生)
- 金币: 9757.4
- 散金: 10
- 红花: 60
- 帖子: 2484
- 在线: 1793小时
- 虫号: 2558361
- 注册: 2013-07-22
- 专业: 肿瘤化学药物治疗
【答案】应助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
yaping221: 金币+30, 翻译EPI+1 2016-03-06 09:30:31
yaping221: 金币+30, 翻译EPI+1 2016-03-06 09:30:31
|
In future personalized medicine enabled by lipidomics and metabolomic may expedite the mission of the right patients receiving the right drug at the right time and dose. Recently more potent drugs including monoclonal antibodies able to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) and inflammatory pathways have been developed to improve current CAD care. 在未来基于脂类组学和代谢组学的个性化医学可以加快对合适病人的选择，以及选对药物，用药时间和剂量的决定。最近, 更为有效的药物，包括能抑制前蛋白转化酶枯草溶菌素 9型（PCSK9）和炎症通路的单克隆抗体已经开发，用于改善冠状动脉疾病的治疗。 However, these novel targeted treatments seem to be at present too expensive to be widely used among all CAD patients. Thus, sensitive biomarkers are needed for identification of patients most suitable for novel innovative treatments and the metabolomic and lipidomic biomarker candidates, in particular the ceramides, hold the potential to become clinically useful companion diagnostics of the future. 然而，在目前看来，这些新的靶向治疗比较昂贵，难以在所有冠状动脉疾病患者中广泛应用。因此，需要用灵敏的生物标志物去确定最合适新疗法以代谢和脂类生物标志物测定的的候选患者, 尤其是神经酰胺，未来有可能成为临床上有用的辅助诊断。 |
2楼2016-03-05 15:38:03